论文部分内容阅读
目的:研究碳酸锂、强的松应用对甲状腺功能亢进症(甲亢)患者131I治疗剂量和疗效的影响。方法:75例甲亢患者随机分为3组:对照组25例,患者仅接受131I治疗;碳酸锂组25例,患者接受131I治疗的同时口服碳酸锂0.75 g/d(从治疗前3 d至治疗后7 d);强的松组25例,患者接受131I治疗的同时口服强的松1 mg/(kg.d),后以每周5 mg逐渐减量至停用。治疗过程中根据甲状腺重量计算治疗需要的131I剂量,6个月后观察患者的治疗效果。结果:与对照组相比,碳酸锂组患者131I剂量明显减少(P<0.05),但治疗效果无明显改善(P>0.05);与对照组相比,强的松组患者131I治疗量有所升高,但无统计学差异(P>0.05),而疗效却明显增加(P<0.05)。结论:碳酸锂可以减少甲亢患者131I治疗的剂量,但对治疗效果无改善作用;强的松对131I治疗剂量无显著影响,但可以增加131I治疗甲亢的疗效。
Objective: To study the effects of lithium carbonate and prednisone on 131I dosage and efficacy in patients with hyperthyroidism (hyperthyroidism). Methods: Seventy-five patients with hyperthyroidism were randomly divided into three groups: control group (n = 25) received only 131I treatment; lithium carbonate group (n = 25) received 131I treatment and oral lithium carbonate 0.75 g / d 7 days later). In the prednisone group, 25 patients received 131I treatment while oral prednisone 1 mg / (kg.d), and then gradually reduced to 5 mg per week to disable. During the course of treatment, 131I dose was calculated according to the weight of thyroid gland, and the therapeutic effect was observed after 6 months. Results: Compared with the control group, the dose of 131I in lithium carbonate group was significantly decreased (P <0.05), but the therapeutic effect was not significantly improved (P> 0.05). Compared with the control group, 131I treatment dose in the prednisone group But no significant difference (P> 0.05), but the effect was significantly increased (P <0.05). CONCLUSION: Lithium carbonate can reduce the dose of 131I in patients with hyperthyroidism, but it has no effect on the treatment effect. Prednisone has no significant effect on the dose of 131I, but can increase the therapeutic effect of 131I in the treatment of hyperthyroidism.